Topline Findings
- Strategic Collaboration: Skyhawk Therapeutics partners with Merck KGaA to leverage the SkySTAR platform to discover RNA-targeting small molecules for neurological disorders.
- Pipeline Expansion: The deal positions Merck KGaA to strengthen its neurology and RNA-focused portfolio, following the recent acquisition of SpringWorks Therapeutics.
- Financial Potential: Skyhawk is eligible for up to $2 billion in milestone and royalty payments, highlighting the commercial value of RNA-modulation therapies.
Skyhawk Therapeutics has entered into a strategic collaboration with Merck KGaA aimed at discovering novel RNA-targeting small molecules for neurological disorders with high unmet need. Leveraging Skyhawk’s SkySTAR platform for RNA splicing modulation, the partnership will focus on advancing innovative approaches in disease areas where traditional therapies have been limited, according to a company press release.
Under terms of the deal, Skyhawk will drive discovery and preclinical development, while Merck KGaA will take on later-stage development and commercialization responsibilities. Additionally, Skyhawk could earn up to $2 billion, including milestone and royalty payments.1
How will the Skyhawk-Merck Collaboration Impact RNA-Targeted Drug Discovery in Neurology?
"Our collaboration with Skyhawk aligns with our strategic focus on innovative science and next-generation technologies that have the potential to deliver impactful medicines to patients with neurological conditions," said Amy Kao, SVP, global head, neuroscience & immunology research unit, Merck KGaA, Darmstadt, Germany, in a press release. "We believe RNA splicing modulation represents an exciting frontier in drug discovery, and Skyhawk's expertise positions them as an ideal partner in this space. It is also in line with our mission in bringing more medicines to more patients, faster."
Merck KGaA Expands Through Strategic Acquisition